{"created":"2023-06-20T16:47:54.655451+00:00","id":19687,"links":{},"metadata":{"_buckets":{"deposit":"e91a69bb-4f5d-4492-a956-618887c79255"},"_deposit":{"created_by":3,"id":"19687","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"19687"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00019687","sets":["14:2667:4459"]},"author_link":["33425"],"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"5","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2017)"}]}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：臨床において、非ステロイド性抗炎症薬（NSAIDs）による消化管障害は重篤な問題である。我々は、このNSAIDs起因性消化管障害の制御を目指し、湿式ビーズミル法を用い、メロキシカム（MLX）ナノ結晶経口製剤を作製した（粒子径48±138 nm, 平均値±標準偏差）。本製剤は、従来の製剤と比較し、4.3倍バイオアベイラビリティが高まり、薬物投与量の減量を可能とした。さらに、これら製剤化に伴うNSAIDs投与量の減少が、薬剤の消化管粘膜直接刺激の低下を介し、障害誘発を軽減することを示した。本成果が安全なNSAIDs療法の確立に繋がることを期待する。\n研究成果の概要（英文）：We designed new oral formulations containing nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam (MLX) solid nanoparticles, and investigate their usefulness by evaluating bioavailability and gastrointestinal lesions. The MLX solid nanoparticles were prepared using a bead mill method, and high quality dispersions containing MLX nanoparticles were prepared (MLXnano, particle size: 48 ± 138 nm, means± S.D.). The bioavailability in MLXnano was 4.3-fold higher in comparison with that in conventional MLX, and the MLX-induced gastrointestinal lesions in rats administered MLXnano, in consideration of bioavailability, were significantly less than for conventional MLX. An oral drug delivery system using drug nanoparticles may expand the usage of NSAIDs for therapy in the inflammatory field.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究(C);  研究期間：2015～2017;   課題番号：15K08115;   研究分野：医療薬学;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_relation_11":{"attribute_name":"著者 外部リンク","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K08115/"}]}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"NAGAI, Noriaki"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学薬学部; 准教授"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"長井, 紀章"},{"creatorName":"ナガイ, ノリアキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-11-20"}],"displaytype":"detail","filename":"15K08115seika.pdf","filesize":[{"value":"496.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"15K08115seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/19687/files/15K08115seika.pdf"},"version_id":"d30030be-83ca-4b08-b197-9d558e0e4a38"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ナノ結晶製剤","subitem_subject_scheme":"Other"},{"subitem_subject":"口腔内崩壊錠","subitem_subject_scheme":"Other"},{"subitem_subject":"NSAIDs","subitem_subject_scheme":"Other"},{"subitem_subject":"消化管傷害","subitem_subject_scheme":"Other"},{"subitem_subject":"関節リウマチ","subitem_subject_scheme":"Other"},{"subitem_subject":"バイオアベイラビリティ","subitem_subject_scheme":"Other"},{"subitem_subject":"ビーズミル","subitem_subject_scheme":"Other"},{"subitem_subject":"湿式破砕","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"ＮＳＡＩＤｓ起因性消化管障害の制御に資する次世代型ナノ製剤の創製とその有用性評価","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ＮＳＡＩＤｓ起因性消化管障害の制御に資する次世代型ナノ製剤の創製とその有用性評価"},{"subitem_title":"Design of novel nanomedicine containing NSAIDs for improvement of drug-induced gastrointestinal lesions","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4459"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-11-20"},"publish_date":"2018-11-20","publish_status":"0","recid":"19687","relation_version_is_last":true,"title":["ＮＳＡＩＤｓ起因性消化管障害の制御に資する次世代型ナノ製剤の創製とその有用性評価"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-20T21:36:04.365354+00:00"}